<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27999" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Pulmonary Alveolar Proteinosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Carrington</surname>
            <given-names>Joseph M.</given-names>
          </name>
          <aff>University of Nebraska Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hershberger</surname>
            <given-names>Daniel M.</given-names>
          </name>
          <aff>University of Nebraska Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Joseph Carrington declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Daniel Hershberger declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>25</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27999.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Pulmonary alveolar proteinosis (PAP) is a rare lung disease involving surfactant accumulation within the alveoli resulting from decreased clearance, rather than increased production. This condition can be congenital, secondary, or autoimmune. Autoimmune PAP is the most common pathophysiologic mechanism accounting for 90 percent of documented cases. This activity reviews the evaluation, treatment, and complications of pulmonary alveolar proteinosis and addresses the importance of an interprofessional team approach to its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the causes of pulmonary alveolar proteinosis.</p></list-item><list-item><p>Describe the presenting features of pulmonary alveolar proteinosis.</p></list-item><list-item><p>Describe the evaluation of pulmonary alveolar proteinosis.</p></list-item><list-item><p>Describe how enhanced coordination of the interprofessional team can lead to more rapid recognition of pulmonary alveolar proteinosis and subsequently improve the evaluation, enhancing detection of pathology and allowing for treatment when indicated.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27999&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27999">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27999.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Pulmonary alveolar proteinosis (PAP) was first described in 1958 by Samuel H. Rosen et al.&#x000a0;<xref ref-type="bibr" rid="article-27999.r1">[1]</xref>. Since that time, clinicians' understanding of this rare lung disease has improved dramatically. Initial reports of this disease described it as respiratory failure secondary to over-production of surfactant proteins within the alveoli <xref ref-type="bibr" rid="article-27999.r2">[2]</xref>. It was believed to be a consequence of inhaled environmental irritants or infectious agents and was&#x000a0;initially called acquired or idiopathic PAP <xref ref-type="bibr" rid="article-27999.r2">[2]</xref>. Practitioners&#x000a0;now understand that there are 3 separate pathways to the development of surfactant accumulation within alveoli: congenital, secondary, and autoimmune <xref ref-type="bibr" rid="article-27999.r3">[3]</xref>. All 3 of these pathways&#x000a0;result in decreased clearance of surfactant, rather than increased production <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Autoimmune PAP is the most common pathophysiologic&#x000a0;mechanism accounting for 90% of documented cases <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Autoimmune PAP is initiated by immunoglobulin (Ig)-G anti-granulocyte macrophage colony stimulating factor (anti-GM-CSF) antibodies, which decrease functional alveolar macrophages <xref ref-type="bibr" rid="article-27999.r3">[3]</xref>. Secondary PAP lacks anti-GM-CSF antibodies&#x000a0;<xref ref-type="bibr" rid="article-27999.r5">[5]</xref> but has decreased functional macrophages secondary to hematological malignancies (myelodysplastic syndrome, chronic myelogenous leukemia, among others) or primary immunodeficiency diseases (common variable immunodeficiency, DiGeorge syndrome, among others) <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Congenital PAP is the least common and results from genetic mutations in GM-CSF receptor proteins or surfactant proteins <xref ref-type="bibr" rid="article-27999.r4">[4]</xref><xref ref-type="bibr" rid="article-27999.r6">[6]</xref>.</p>
      </sec>
      <sec id="article-27999.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Autoimmune PAP is a direct consequence of antibodies against GM-CSF <xref ref-type="bibr" rid="article-27999.r7">[7]</xref>. There has been speculation that cigarette smoke or infectious diseases stimulate the development of these autoantibodies due to a high prevalence of smoking and infections in patients with PAP <xref ref-type="bibr" rid="article-27999.r2">[2]</xref>. However, no causal link has been found between cigarette smoke and autoimmune PAP <xref ref-type="bibr" rid="article-27999.r2">[2]</xref>. Additionally, no causal link has been found between infections and autoimmune PAP <xref ref-type="bibr" rid="article-27999.r2">[2]</xref>.</p>
        <p>Secondary PAP is caused by any disease that reduces the functionally effective alveolar macrophage population <xref ref-type="bibr" rid="article-27999.r6">[6]</xref>. In one retrospective analysis, 34.1% of secondary PAP was associated with myelodysplastic syndrome, and 15.2% was associated with chronic myelogenous leukemia <xref ref-type="bibr" rid="article-27999.r5">[5]</xref>. Acute myeloid leukemia also has a well-established association with PAP <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Less frequent are associations between PAP and acute lymphoid leukemia, lymphoma, and myeloma <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Few case reports have associated PAP with non-hematological cancers such as lung cancer, mesothelioma, and glioblastoma <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Rare reports have associated PAP with immunodeficiencies such as severe combined immunodeficiency, agammaglobulinemia, adenosine deaminase deficiency, common variable immunodeficiency, DiGeorge syndrome, dermatomyositis, rheumatoid arthritis, Behcet&#x02019;s disease, AIDS, GATA2 deficiency, and organ transplantation <xref ref-type="bibr" rid="article-27999.r4">[4]</xref><xref ref-type="bibr" rid="article-27999.r8">[8]</xref><xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Secondary PAP has also been associated with inhalation of several environmental exposures <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. These environmental exposures include silica, talc, cement, kaolin, aluminum, titanium, indium, and cellulose <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Several animal studies have induced PAP following inhalation of aluminum, fiberglass, indium, nickel, quartz, silica, and titanium <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. French analysis of PAP patients found that 39% had an environmental exposure of cement, cereal dust, copper, epoxy, paint, polyvinyl chloride, silica, welding, wood dust, zirconium, or smoke <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. A report from Japan showed that 23% of patients with PAP had significant environmental exposures <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. A Korean study reported 53% of PAP patients were smokers and 48% had exposure to dust <xref ref-type="bibr" rid="article-27999.r9">[9]</xref>. These dust exposures included metal (26.5%), stone or sand (20.6%), chemical or paint (17.7%), farming dust (14.7%), diesel (14.7%), textile (2.9%), and wood (2.9%) <xref ref-type="bibr" rid="article-27999.r9">[9]</xref>. One report suggests a link between indium inhalation and anti-GM-CSF antibodies, suggesting these toxic inhalations might induce autoantibodies <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>.</p>
        <p>Hereditary dysfunction in one of many proteins responsible for surfactant regulation causes&#x000a0;Congenital PAP <xref ref-type="bibr" rid="article-27999.r4">[4]</xref><xref ref-type="bibr" rid="article-27999.r6">[6]</xref>. This includes mutations in the GM-CSF receptor alpha-subunit or beta-subunit, surfactant protein B, surfactant protein C, ATP-binding cassette 3, NK2 homeobox 1, or the lysinuric protein intolerance disease <xref ref-type="bibr" rid="article-27999.r4">[4]</xref><xref ref-type="bibr" rid="article-27999.r6">[6]</xref>.</p>
      </sec>
      <sec id="article-27999.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>PAP is a rare lung disease <xref ref-type="bibr" rid="article-27999.r10">[10]</xref>. Prevalence has been reported to be from 3.7 to 40 cases per million depending on the country <xref ref-type="bibr" rid="article-27999.r2">[2]</xref><xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. The incidence has been estimated to be 0.2 cases per million <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Autoimmune PAP accounts for approximately 90% of cases, while 4% is secondary PAP, 1% is congenital PAP, and undetermined PAP-like disease represents the remaining 5% <xref ref-type="bibr" rid="article-27999.r2">[2]</xref><xref ref-type="bibr" rid="article-27999.r11">[11]</xref>. Smoking is reported in 53% to 85% of PAP patients <xref ref-type="bibr" rid="article-27999.r4">[4]</xref><xref ref-type="bibr" rid="article-27999.r9">[9]</xref>.</p>
        <p>In autoimmune PAP, males are more commonly affected than females at a 2:1 ratio <xref ref-type="bibr" rid="article-27999.r11">[11]</xref>. Median age at time-of-diagnosis is reported from 39 years to 51 years, although ages range from newborn to 72 years old <xref ref-type="bibr" rid="article-27999.r2">[2]</xref><xref ref-type="bibr" rid="article-27999.r4">[4]</xref>.&#x000a0;</p>
        <p>Secondary PAP has been reported with a slightly younger median age at time-of-diagnosis; 37 years to 45 years <xref ref-type="bibr" rid="article-27999.r5">[5]</xref>. Gender-ratio is also different in secondary PAP, with a 1.2:1 male to female ratio <xref ref-type="bibr" rid="article-27999.r5">[5]</xref>.</p>
      </sec>
      <sec id="article-27999.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>
<bold>Surfactant</bold>
</p>
        <p>Surfactant is a key component within alveoli that prevents end-expiratory collapse by decreasing alveolar surface tension at the air-liquid interface <xref ref-type="bibr" rid="article-27999.r2">[2]</xref><xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Surfactant is also crucial for host defense at the alveolar level by opsonizing microbes and signaling innate defense mechanisms&#x000a0;<xref ref-type="bibr" rid="article-27999.r2">[2]</xref><xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. It is&#x000a0;synthesized and secreted by alveolar type II epithelial cells&#x000a0;<xref ref-type="bibr" rid="article-27999.r4">[4]</xref><xref ref-type="bibr" rid="article-27999.r6">[6]</xref>. Both type II epithelial cells and alveolar macrophages are involved in the breakdown and clearance of surfactant <xref ref-type="bibr" rid="article-27999.r4">[4]</xref><xref ref-type="bibr" rid="article-27999.r6">[6]</xref>. Surfactant is made of approximately 90% lipid, most of which is phosphatidylcholine&#x000a0;<xref ref-type="bibr" rid="article-27999.r2">[2]</xref><xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. The&#x000a0;next 9% of surfactant is protein, and the&#x000a0;remaining 1% is carbohydrate <xref ref-type="bibr" rid="article-27999.r2">[2]</xref>. There are 4 main subtypes of surfactant known as surfactant proteins A, B, C, and D&#x000a0;<xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Each of these molecules corresponds to the genes <italic toggle="yes">SFTPA</italic>, <italic toggle="yes">SFTPB</italic>, <italic toggle="yes">SFTPC</italic>, and <italic toggle="yes">SFPTD</italic>&#x000a0;<xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Mutations in these genes lead to malformed surfactant which accumulates within type II alveolar epithelial cells, causing ineffective clearance of surfactant from the alveoli and cell death&#x000a0;<xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. When PAP was first described in 1958, patients were noted to have eosinophilic materials in their alveoli that were filled with lipids and some proteins and carbohydrates <xref ref-type="bibr" rid="article-27999.r1">[1]</xref>. Since that time, it has been confirmed that&#x000a0;the eosinophilic material&#x000a0;is indeed surfactant&#x000a0;accumulation&#x000a0;<xref ref-type="bibr" rid="article-27999.r2">[2]</xref>.</p>
        <p>
<bold>GM-CSF</bold>
</p>
        <p>GM-CSF is a crucial cytokine involved in host defense of pulmonary bacterial, viral, and fungal infections <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Antibodies that interfere with this cytokine can lead to increased opportunistic infections <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>.&#x000a0;</p>
        <p>In 1994, researchers discovered that GM-CSF is important in the pathophysiology of PAP when GM-CSF knock-out mice demonstrated PAP-like disease <xref ref-type="bibr" rid="article-27999.r12">[12]</xref>. GM-CSF is a 23-kD growth factor cytokine <xref ref-type="bibr" rid="article-27999.r2">[2]</xref>. GM-CSF binds to various cells via cell-surface receptors to induce biological effects of differentiation, proliferation, and survival <xref ref-type="bibr" rid="article-27999.r2">[2]</xref><xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. The affected cells include monocytes, neutrophils, dendritic cells, macrophages, and type II alveolar epithelial cells <xref ref-type="bibr" rid="article-27999.r2">[2]</xref>. When anti-GM-CSF antibodies are formed, as with autoimmune PAP, they bind with high affinity to GM-CSF and block their biological potential <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. This leads to dysfunctional alveolar macrophages&#x000a0;which&#x000a0;are unable to clear surfactant <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Instead, these macrophages accumulate large lysosomes filled with surfactant and become defective in normal anti-microbial activities such as phagocytosis, chemotaxis, superoxide production, pathogen-recognition receptor expression, cytokine release, and cellular adhesion <xref ref-type="bibr" rid="article-27999.r2">[2]</xref>. Furthermore, lymphocytes and neutrophils are less functional which leads to an increase in opportunistic infections <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. In GM-CSF knock out mice, messenger RNA of the surfactant proteins was not increased, indicating that surfactant overproduction is not involved in the development of PAP <xref ref-type="bibr" rid="article-27999.r2">[2]</xref>. This model&#x000a0;instead demonstrated decreased clearance of surfactant&#x000a0;as evidenced by the accumulation of lipoprotein in macrophages and eosinophils <xref ref-type="bibr" rid="article-27999.r2">[2]</xref>. Under ultra-microscopy, the lipoprotein material within the eosinophils and macrophages consists of tubular myelin, lamellar bodies, surfactant phospholipids, and surfactant proteins <xref ref-type="bibr" rid="article-27999.r2">[2]</xref>.</p>
        <p>
<bold>Autoimmune PAP</bold>
</p>
        <p>GM-CSF levels are normal in bronchoalveolar lavage fluid (BALF) in autoimmune PAP <xref ref-type="bibr" rid="article-27999.r2">[2]</xref>. However, elevated IgG anti-GM-CSF&#x000a0;levels&#x000a0;are&#x000a0;observed in BALF and serum in autoimmune PAP patients <xref ref-type="bibr" rid="article-27999.r2">[2]</xref>. Elevated levels are not seen in other&#x000a0;lung diseases <xref ref-type="bibr" rid="article-27999.r2">[2]</xref>.&#x000a0;</p>
        <p>
<bold>Secondary PAP</bold>
</p>
        <p>In secondary PAP, it is believed that the underlying hematological disease causes either a reduction in the number of alveolar macrophages or a reduction in the functional quality of these macrophages <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. At least 3 patients with acute myeloid leukemia have been found to have a defect in the expression of GM-CSF receptor on alveolar macrophages <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Following successful treatment of underlying leukemia, the receptor expression returned to normal in these individuals <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>.</p>
        <p>
<bold>Congenital PAP</bold>
</p>
        <p>In congenital PAP, surfactant accumulation is a consequence of a genetic mutation resulting in dysfunctional GM-CSF receptor activation <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. In humans, the GM-CSF receptor is composed of an alpha and a beta subunit, each which corresponds to the genes <italic toggle="yes">CSF2RA</italic> and <italic toggle="yes">CSF2RB</italic> respectively <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Mutations in <italic toggle="yes">CSF2RA</italic> have been reported in young children (newborn to 9 years) with an autosomal recessive inheritance pattern with incomplete penetrance <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Mutations in <italic toggle="yes">CSF2RB</italic> are less common and have been reported from newborns up to 36 years old <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Either mutation leads to an increased GM-CSF level in BALF and serum <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Congenital PAP has also been described in lysinuric protein intolerance, which is an autosomal recessive disease caused by a mutation in SLC7A7 and leads to defective transport of amino acids at the epithelial membrane <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. This disease presents at an early age with gastrointestinal, renal, and less commonly pulmonary manifestations <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. <italic toggle="yes">SLC7A7</italic> mutations lead to dysfunctional arginine transport and dysfunctional alveolar macrophages <xref ref-type="bibr" rid="article-27999.r13">[13]</xref>. Although <italic toggle="yes">SLC7A7</italic> is a target of GM-CSF, which upregulates it, the GM-CSF pathway does not seem to be altered in this disease or lead to PAP <xref ref-type="bibr" rid="article-27999.r13">[13]</xref>. Mutations in surfactant protein B, surfactant protein C, ATP-binding cassette 3, or NK2 homeobox can all lead to dysfunctional surfactant release from type II epithelial cells and dysfunctional clearance from the alveoli <xref ref-type="bibr" rid="article-27999.r14">[14]</xref>.</p>
        <p>Whatever the inciting factor, all of these pathways lead to the same end: accumulation of lipoproteinaceous material in the alveoli due to dysfunctional clearance by alveolar macrophages or type II epithelial cells.</p>
      </sec>
      <sec id="article-27999.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The initial gross description of lungs from PAP patients during autopsy revealed multiple yellow-grey nodules measuring from a few millimeters to 2 centimeters throughout the lung <xref ref-type="bibr" rid="article-27999.r1">[1]</xref>. These nodules were firm, but upon dissection, they leaked a thick, milky substance with palpation <xref ref-type="bibr" rid="article-27999.r1">[1]</xref>. General light-microscopy with hematoxylin and eosin staining showed preserved interalveolar septa with lipoproteinaceous material filling the alveoli and some bronchioles <xref ref-type="bibr" rid="article-27999.r1">[1]</xref>. The epithelial cells lining the alveoli and bronchioles were damaged and sloughed from the wall, while large mononuclear cells were present <xref ref-type="bibr" rid="article-27999.r1">[1]</xref>. A more recent examination of surgical lung biopsies demonstrated persevered lung parenchyma with peribronchial lymphocytic infiltrations and alveoli filled with macrophages and amorphic eosinophilic material that stains periodic-acid-Schiff (PAS)-positive <xref ref-type="bibr" rid="article-27999.r2">[2]</xref><xref ref-type="bibr" rid="article-27999.r6">[6]</xref>. Immunohistochemical staining of this material confirms surfactant protein <xref ref-type="bibr" rid="article-27999.r2">[2]</xref>. BALF cellularity is often increased with a predominance of lymphocytes <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Cytological examination of the BALF shows foamy macrophages which contain eosinophilic granules and amorphic material that stains PAS-positive <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>.&#x000a0;High-powered microscopy of BALF, although not routinely done, shows lamellar bodies&#x000a0;that resemblance myelin <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. The rare&#x000a0;cases of congenital PAP&#x000a0;may&#x000a0;demonstrate varying degrees of interstitial remodeling and type-II epithelial cell hyperplasia on biopsy <xref ref-type="bibr" rid="article-27999.r4">[4]</xref><xref ref-type="bibr" rid="article-27999.r14">[14]</xref>.</p>
      </sec>
      <sec id="article-27999.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Clinical presentation of PAP varies from indolent to emergent and symptoms are often non-specific <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Dyspnea is the most common presenting complaint; present in 39% of patients in one report <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. A cough was reported in 21% of patients <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>.&#x000a0;Hemoptysis, fever, and chest pain are rare complaints of autoimmune PAP and should prompt consideration of another diagnosis <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Fever may be present in 24% of secondary PAP patients due to concomitant hematological malignancies or opportunistic infections <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Thirty-three percent of patients may be asymptomatic at the time of presentation <xref ref-type="bibr" rid="article-27999.r3">[3]</xref>.&#x000a0;</p>
        <p>A majority of patients are smokers (53% to 85%) <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Many&#x000a0;report occupational exposures (39% to 48%) <xref ref-type="bibr" rid="article-27999.r9">[9]</xref>. Even though 90% of PAP cases are autoimmune, only 1.7% of patients have other identified autoimmune diseases <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Physical examination is frequently normal; however, patients can present with cyanosis (25% to 30%), clubbing (30%), or inspiratory crackles (50%) <xref ref-type="bibr" rid="article-27999.r2">[2]</xref><xref ref-type="bibr" rid="article-27999.r4">[4]</xref>.</p>
      </sec>
      <sec id="article-27999.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Given that the clinical presentation of PAP is nonspecific, diagnosis of this disease demands appropriate serological, radiological, and bronchoscopic evaluation.</p>
        <p>
<bold>Radiography</bold>
</p>
        <p>Chest radiography may demonstrate bilateral alveolar opacities in a peri-hilar and basilar distribution without air-bronchograms <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. This is sometimes referred to as a &#x0201c;batwing distribution,&#x0201d; or may resemble pulmonary edema without cardiomegaly or pleural effusions <xref ref-type="bibr" rid="article-27999.r3">[3]</xref><xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Computed tomography reveals intralobular thickening and diffuse ground-glass opacities <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. This pattern is often referred to as &#x0201c;crazy paving.&#x0201d; "Crazy paving" is&#x000a0;highly suggestive of PAP although not specific or sensitive enough to confirm the diagnosis <xref ref-type="bibr" rid="article-27999.r3">[3]</xref><xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Lower-lobe predominance has been reported&#x000a0;in 22% of cases <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Pulmonary nodules, mediastinal adenopathy, and focal parenchymal consolidations are absent in PAP and should prompt consideration of a different diagnosis <xref ref-type="bibr" rid="article-27999.r4">[4]</xref><xref ref-type="bibr" rid="article-27999.r8">[8]</xref>. Secondary PAP is less likely to have interlobular septal thickening (only 33.3% of cases) <xref ref-type="bibr" rid="article-27999.r4">[4]</xref><xref ref-type="bibr" rid="article-27999.r5">[5]</xref>. Congenital PAP is also less likely to present with interlobular septal thickening and additionally may present with lung cysts <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>.</p>
        <p>
<bold>Biomarkers</bold>
</p>
        <p>Several biomarkers have been studied in PAP, including surfactant protein A, B, and D levels, cytokeratin 19, serum carcinoembryonic antigen, serum lactate dehydrogenase, GM-CSF levels, anti-GM-CSF antibodies, and KL-6 <xref ref-type="bibr" rid="article-27999.r6">[6]</xref><xref ref-type="bibr" rid="article-27999.r15">[15]</xref>. Serum lactate dehydrogenase is elevated in 50% of PAP patients and serum carcinoembryonic antigen is also often elevated <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Serum levels of the surfactant protein A, B, and D are all increased in PAP and seem to be associated with disease severity <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Overall, these biomarkers have not proven sensitive or specific for diagnosis <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Testing for IgG anti-GM-CSF antibodies is the only clinically relevant biomarker to date <xref ref-type="bibr" rid="article-27999.r12">[12]</xref>. Detection of these antibodies is done via enzyme-linked immunosorbent assay (ELISA) which is the gold-standard and has been validated <xref ref-type="bibr" rid="article-27999.r12">[12]</xref><xref ref-type="bibr" rid="article-27999.r16">[16]</xref>. Serum antibody levels can also be detected via latex-agglutination test with 100% sensitivity and 98% specificity <xref ref-type="bibr" rid="article-27999.r2">[2]</xref>. An anti-GM-CSF antibody level of&#x000a0;2.8 micrograms/ml or&#x000a0;greater is abnormal and is consistent with PAP <xref ref-type="bibr" rid="article-27999.r17">[17]</xref>.</p>
        <p>
<bold>Pulmonary Function Testing</bold>
</p>
        <p>Pulmonary function testing is not necessary for diagnosis, nor is it specific for PAP; however, the most common pattern on spirometry is a restrictive pattern <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Spirometry may be normal in 30% of patients with PAP and may have a mixed obstruction and restrictive pattern in those who are smokers <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. A significant reduction in diffusion capacity and an increase in the alveolar-arterial gradient are the most common findings on pulmonary function testing in patients with PAP <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>.</p>
        <p>
<bold>Bronchoscopy</bold>
</p>
        <p>When PAP is suspected, bronchoscopy with bronchoalveolar lavage is the gold standard for diagnosis <xref ref-type="bibr" rid="article-27999.r2">[2]</xref><xref ref-type="bibr" rid="article-27999.r3">[3]</xref><xref ref-type="bibr" rid="article-27999.r4">[4]</xref><xref ref-type="bibr" rid="article-27999.r6">[6]</xref>. In approximately 75% of suspected cases, BALF examination will confirm a diagnosis <xref ref-type="bibr" rid="article-27999.r2">[2]</xref>. The lavage return will often appear milky and opaque <xref ref-type="bibr" rid="article-27999.r4">[4]</xref><xref ref-type="bibr" rid="article-27999.r6">[6]</xref>. BALF cytological examination will reveal large foamy macrophages with amorphous material that stains PAS-positive <xref ref-type="bibr" rid="article-27999.r2">[2]</xref>. BALF cellularity&#x000a0;is typically&#x000a0;lymphocyte-predominant <xref ref-type="bibr" rid="article-27999.r2">[2]</xref>. Secondary PAP may be associated with opportunistic infections which can lead to mixed cellularity, microbial growth, and potential for a missed diagnosis of PAP (only 61.9% of secondary PAP cases diagnosed with bronchoscopy) <xref ref-type="bibr" rid="article-27999.r4">[4]</xref><xref ref-type="bibr" rid="article-27999.r5">[5]</xref>.</p>
        <p>
<bold>Lung Biopsy</bold>
</p>
        <p>Biopsies are not necessary for a&#x000a0;diagnosis of PAP but can be helpful <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Open-lung biopsy or video-assisted thoracic surgery is rarely done but will demonstrate PAS-positive lipoproteinaceous material <xref ref-type="bibr" rid="article-27999.r4">[4]</xref><xref ref-type="bibr" rid="article-27999.r6">[6]</xref>. Transbronchial biopsies were found to positively diagnose PAP in 42% of cases in one study <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. There is at least one report of a bronchoscopic cryobiopsy resulting in a diagnosis of PAP in a patient with otherwise normal BALF and negative for anti-GM-CSF antibodies <xref ref-type="bibr" rid="article-27999.r18">[18]</xref>.</p>
      </sec>
      <sec id="article-27999.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Whole Lung Lavage</bold>
</p>
        <p>The current standard of care for autoimmune PAP is whole lung lavage (WLL)<xref ref-type="bibr" rid="article-27999.r2">[2]</xref><xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. The decision to treat is based upon signs of poor gas exchange and symptoms of respiratory distress <xref ref-type="bibr" rid="article-27999.r3">[3]</xref>. Patients with mild dyspnea or no symptoms can do well with supportive care and monitoring of pulmonary function tests and chest imaging <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Whole lung lavage should be considered in patients with dyspnea at rest, resting PaO2 less than 65 mm Hg, resting alveolar-arterial gradient greater than 40 mm Hg or oxygen desaturations on 6-minute walk test <xref ref-type="bibr" rid="article-27999.r3">[3]</xref><xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. WLL was first performed in 1961 <xref ref-type="bibr" rid="article-27999.r2">[2]</xref><xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Today, the procedure is done under general anesthesia with a double lumen endotracheal tube <xref ref-type="bibr" rid="article-27999.r2">[2]</xref><xref ref-type="bibr" rid="article-27999.r3">[3]</xref><xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. One lung is ventilated while the contralateral lung is lavaged with warm saline (37 C) and then allowed to drain to gravity <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. This process is continued until the returning fluid is clear <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>.&#x000a0; An average of 15 liters of saline&#x000a0;is&#x000a0;required <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. The procedure is repeated on the contralateral lung after 48 hours or more <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. A global analysis of WLL therapy showed that centers differ in the time between lavaging the contralateral lung (50% wait 1 to 2 weeks), the choice of lung to begin with, the position of the patient (50% supine, 50% lateral decubitus), chest percussion use during the procedure, and amount of saline used (5 to 40 L) <xref ref-type="bibr" rid="article-27999.r19">[19]</xref>. Retrospective studies of WLL have shown several parameters improve after therapy. Symptomatic improvement occurs in 85% of cases <xref ref-type="bibr" rid="article-27999.r2">[2]</xref><xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Radiographic findings also improve <xref ref-type="bibr" rid="article-27999.r2">[2]</xref><xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Forced expiratory volume in 1 second (FEV1) improves by 0.26 L, forced vital capacity (FVC) improves by 0.5 L, diffusion capacity improves by 4.4 mL, and alveolar-arterial gradient improves by 30 mm Hg <xref ref-type="bibr" rid="article-27999.r2">[2]</xref><xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Retrospective data also suggests a mortality benefit (94% at 5 years with WLL compared to 85% at 5 years without WLL) <xref ref-type="bibr" rid="article-27999.r2">[2]</xref><xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. WLL has not been verified in randomized prospective trials <xref ref-type="bibr" rid="article-27999.r2">[2]</xref>. Approximately 50% of patients will require a second WLL procedure <xref ref-type="bibr" rid="article-27999.r5">[5]</xref>. The average duration of benefits following WLL is 15 months <xref ref-type="bibr" rid="article-27999.r2">[2]</xref>. A review found that 70% of patients underwent WLL within 5 years of diagnosis and that on average patients required two whole lung lavages <xref ref-type="bibr" rid="article-27999.r13">[13]</xref>.</p>
        <p>
<bold>GM-CSF Replacement Therapy</bold>
</p>
        <p>Clinical trials for GM-CSF replacement therapy were performed in the late 1990s <xref ref-type="bibr" rid="article-27999.r2">[2]</xref>. Subcutaneous injections of GM-CSF showed a positive response in 48% of a small cohort of 25 patients <xref ref-type="bibr" rid="article-27999.r2">[2]</xref><xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Improvement following GM-CSF injections was much slower than the standard WLL, and therefore, this therapy has fallen out of favor <xref ref-type="bibr" rid="article-27999.r2">[2]</xref><xref ref-type="bibr" rid="article-27999.r4">[4]</xref><xref ref-type="bibr" rid="article-27999.r2">[2]</xref>. In a small trial of 12 patients of inhaled GM-CSF therapy, 11 of patients (91%) showed improvement <xref ref-type="bibr" rid="article-27999.r2">[2]</xref><xref ref-type="bibr" rid="article-27999.r4">[4]</xref><xref ref-type="bibr" rid="article-27999.r2">[2]</xref>. However, a larger subsequent trial of 35 patients resulted in only 68% of patients showing improvement <xref ref-type="bibr" rid="article-27999.r2">[2]</xref><xref ref-type="bibr" rid="article-27999.r4">[4]</xref><xref ref-type="bibr" rid="article-27999.r2">[2]</xref>. These therapies are safe and show some improvement in autoimmune PAP; they were ineffective in congenital PAP and inferior to WLL <xref ref-type="bibr" rid="article-27999.r2">[2]</xref><xref ref-type="bibr" rid="article-27999.r6">[6]</xref>. These are currently considered alternative therapies to WLL <xref ref-type="bibr" rid="article-27999.r2">[2]</xref>.</p>
        <p>
<bold>Immunomodulation Therapy</bold>
</p>
        <p>Systemic corticosteroids were trialed in autoimmune PAP but were ineffective, and they were found to increase the risk of pulmonary infections <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Plasmapheresis has been reported to decrease circulating anti-GM-CSF in 2 cases successfully <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. One of these patients demonstrated significant clinical improvements while the other did not <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Rituximab, an anti-CD20 therapy, was studied in 2010 in 10 patients <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Eight of these patients had significant clinical improvement despite no change in serum anti-GM-CSF levels <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Both Rituximab and plasmapheresis are considered alternative therapies for PAP refractory to WLL <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>.</p>
        <p>
<bold>Secondary PAP</bold>
</p>
        <p>The only proven therapy for secondary PAP is the treatment of the underlying disease <xref ref-type="bibr" rid="article-27999.r6">[6]</xref>. Case reports have demonstrated return of functional alveolar macrophages following the appropriate treatment of leukemia <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. WLL does not seem to benefit this population as only two of 14 patients studied had clinical improvement <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Allogeneic hematopoietic stem cell transplant is a potential treatment option with two reported cases of complete resolution of secondary PAP after transplant <xref ref-type="bibr" rid="article-27999.r8">[8]</xref>.</p>
        <p>
<bold>Congenital PAP</bold>
</p>
        <p>WLL may benefit patients with congenital PAP, but is not curative <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. GM-CSF replacement therapies have not shown effectiveness <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Corticosteroids and steroid-sparing agents such as azathioprine have been used at some centers with mixed results <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Animal models show promise with gene therapy and direct pulmonary macrophage transplantation resulting in complete resolution of PAP <xref ref-type="bibr" rid="article-27999.r6">[6]</xref><xref ref-type="bibr" rid="article-27999.r20">[20]</xref>. At least one patient has had successful hematopoietic stem cell transplant, which cured their PAP, but this therapy carries potential risks of graft-versus-host disease and opportunistic infections <xref ref-type="bibr" rid="article-27999.r7">[7]</xref>.</p>
      </sec>
      <sec id="article-27999.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of pulmonary alveolar proteinosis includes diseases that share restrictive physiology and diffuse interstitial changes on computed tomography. Although a &#x0201c;crazy paving&#x0201d; pattern on computed tomography is suggestive of PAP, it can also be associated with cardiogenic pulmonary edema, acute respiratory distress syndrome, alveolar hemorrhage, lipoid pneumonia, mycoplasma pneumonia, pneumocystis pneumonia, radiation pneumonitis, drug-induced pneumonitis, sarcoidosis, non-specific interstitial pneumonitis, or bronchioloalveolar carcinoma. Acute silicosis can present with the same clinical and pathologic findings as PAP. Acute silicosis can display radiographic &#x0201c;crazy paving,&#x0201d; milky BALF with foamy macrophages, and PAS-positive amorphous material within the alveolus on biopsy. The similarities between acute silicosis and PAP emphasize the importance of a&#x000a0;thorough occupational history for recent silica exposure.</p>
      </sec>
      <sec id="article-27999.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Disease course varies, and the prognosis is unpredictable. When treated with whole lung lavage, the 5-year survival of autoimmune PAP is 95% <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. Previously spontaneous remission had been reported as frequently as 50% of the time <xref ref-type="bibr" rid="article-27999.r11">[11]</xref><xref ref-type="bibr" rid="article-27999.r21">[21]</xref>. However, more recent and more extensive analyses have concluded that spontaneous remission occurs in less than 10% of patients <xref ref-type="bibr" rid="article-27999.r19">[19]</xref>. In one prospective cohort study of 39 asymptomatic PAP patients, 64% of patients remained stable while 7%&#x000a0;progressed <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. In a retrospective analysis of mortality in PAP patients, 72% of deaths occurred as a direct result of respiratory failure while 20% were&#x000a0;due to secondary infections <xref ref-type="bibr" rid="article-27999.r2">[2]</xref>. The prognosis for secondary PAP is worse with a median time for survival less than 15 months <xref ref-type="bibr" rid="article-27999.r4">[4]</xref><xref ref-type="bibr" rid="article-27999.r5">[5]</xref><xref ref-type="bibr" rid="article-27999.r4">[4]</xref>. The causes of death in secondary PAP patients include the underlying hematological disease (33%), infection (25%), respiratory failure (25%), and bleeding complications (13%) <xref ref-type="bibr" rid="article-27999.r4">[4]</xref>.</p>
      </sec>
      <sec id="article-27999.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Patients with PAP are at an increased risk of developing an opportunistic infection with approximately 5% of PAP patients developing one <xref ref-type="bibr" rid="article-27999.r22">[22]</xref><xref ref-type="bibr" rid="article-27999.r23">[23]</xref>. The lung is the most common site of infection, although extra-pulmonary infections represent 32% of opportunistic infections in PAP patients <xref ref-type="bibr" rid="article-27999.r22">[22]</xref><xref ref-type="bibr" rid="article-27999.r23">[23]</xref>. Typical bacterial cases of pneumonia are possible but infrequently reported in PAP <xref ref-type="bibr" rid="article-27999.r22">[22]</xref><xref ref-type="bibr" rid="article-27999.r23">[23]</xref>. <italic toggle="yes">Nocardia</italic> and <italic toggle="yes">Mycobacterium tuberculosis </italic>are the 2 most commonly reported opportunistic infections in PAP <xref ref-type="bibr" rid="article-27999.r22">[22]</xref><xref ref-type="bibr" rid="article-27999.r23">[23]</xref>. Fungal infections reported include <italic toggle="yes">Histoplasma</italic>, <italic toggle="yes">Aspergillus</italic>, <italic toggle="yes">Cryptococcus</italic>, and <italic toggle="yes">Blastomyces&#x000a0;</italic><xref ref-type="bibr" rid="article-27999.r22">[22]</xref><xref ref-type="bibr" rid="article-27999.r23">[23]</xref>. Other reported infections include <italic toggle="yes">Acinetobacter</italic>, <italic toggle="yes">Coccidiodies</italic>, <italic toggle="yes">Mucorales</italic>, and <italic toggle="yes">Streptomyces&#x000a0;</italic><xref ref-type="bibr" rid="article-27999.r22">[22]</xref><xref ref-type="bibr" rid="article-27999.r23">[23]</xref>.</p>
      </sec>
      <sec id="article-27999.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Pulmonary Alveolar Proteinosis is a rare disease that is difficult to diagnose and treat. an interprofessional&#x000a0;team effort of specialty trained clinicians and nurses is required to successfully provide the best care for these patients. [Level V]</p>
      </sec>
      <sec id="article-27999.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27999&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27999">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/lung-disease-respiratory-health/pulmonary-alveolar-proteinosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=27999">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27999/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27999">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-27999.s15">
        <title>References</title>
        <ref id="article-27999.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>ROSEN</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>CASTLEMAN</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>LIEBOW</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary alveolar proteinosis.</article-title>
            <source>N Engl J Med</source>
            <year>1958</year>
            <month>Jun</month>
            <day>05</day>
            <volume>258</volume>
            <issue>23</issue>
            <fpage>1123</fpage>
            <page-range>1123-42</page-range>
            <pub-id pub-id-type="pmid">13552931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27999.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trapnell</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Whitsett</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Nakata</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary alveolar proteinosis.</article-title>
            <source>N Engl J Med</source>
            <year>2003</year>
            <month>Dec</month>
            <day>25</day>
            <volume>349</volume>
            <issue>26</issue>
            <fpage>2527</fpage>
            <page-range>2527-39</page-range>
            <pub-id pub-id-type="pmid">14695413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27999.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kamboj</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lause</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Duggirala</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Severe Pulmonary Alveolar Proteinosis in a Young Adult.</article-title>
            <source>Am J Med</source>
            <year>2018</year>
            <month>May</month>
            <volume>131</volume>
            <issue>5</issue>
            <fpage>e199</fpage>
            <page-range>e199-e200</page-range>
            <pub-id pub-id-type="pmid">29307537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27999.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Borie</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Danel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Debray</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Taille</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dombret</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Aubier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Epaud</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Crestani</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary alveolar proteinosis.</article-title>
            <source>Eur Respir Rev</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>20</volume>
            <issue>120</issue>
            <fpage>98</fpage>
            <page-range>98-107</page-range>
            <pub-id pub-id-type="pmid">21632797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27999.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Situ</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>KF</given-names>
              </name>
            </person-group>
            <article-title>Secondary pulmonary alveolar proteinosis: a single-center retrospective study (a case series and literature review).</article-title>
            <source>BMC Pulm Med</source>
            <year>2018</year>
            <month>Jan</month>
            <day>25</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <pub-id pub-id-type="pmid">29368649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27999.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McElvaney</surname>
                <given-names>OJ</given-names>
              </name>
              <name>
                <surname>Horan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Franciosi</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Gunaratnam</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>McElvaney</surname>
                <given-names>NG</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary alveolar proteinosis.</article-title>
            <source>QJM</source>
            <year>2018</year>
            <month>Mar</month>
            <day>01</day>
            <volume>111</volume>
            <issue>3</issue>
            <fpage>185</fpage>
            <page-range>185-186</page-range>
            <pub-id pub-id-type="pmid">29240908</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27999.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fr&#x000e9;mond</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Hadchouel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schweitzer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Berteloot</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bruneau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bonnet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cros</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Briand</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Magnani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pochon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Delacourt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cavazzana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moshous</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blanche</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Blic</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Neven</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Successful haematopoietic stem cell transplantation in a case of pulmonary alveolar proteinosis due to GM-CSF receptor deficiency.</article-title>
            <source>Thorax</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>73</volume>
            <issue>6</issue>
            <fpage>590</fpage>
            <page-range>590-592</page-range>
            <pub-id pub-id-type="pmid">29263235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27999.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanaka-Kubota</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shinozaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Miyamoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yanagimachi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Okano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mitsuiki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ueki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Imai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takagi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Agematsu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kanegane</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Morio</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Hematopoietic stem cell transplantation for pulmonary alveolar proteinosis associated with primary immunodeficiency disease.</article-title>
            <source>Int J Hematol</source>
            <year>2018</year>
            <month>May</month>
            <volume>107</volume>
            <issue>5</issue>
            <fpage>610</fpage>
            <page-range>610-614</page-range>
            <pub-id pub-id-type="pmid">29185156</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27999.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hwang</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Cha</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Uh</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Jeong</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>YB</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Jegal</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Clinical significance of cigarette smoking and dust exposure in pulmonary alveolar proteinosis: a Korean national survey.</article-title>
            <source>BMC Pulm Med</source>
            <year>2017</year>
            <month>Nov</month>
            <day>21</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>147</fpage>
            <pub-id pub-id-type="pmid">29162083</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27999.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCarthy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lara Gallego</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Trapnell</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>McCormack</surname>
                <given-names>FX</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of Rare Lung Diseases: The Challenges and Opportunities to Improve Research and Knowledge.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>2017</year>
            <volume>1031</volume>
            <fpage>419</fpage>
            <page-range>419-442</page-range>
            <pub-id pub-id-type="pmid">29214586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27999.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campo</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mariani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rodi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Paracchini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tsana</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Piloni</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nobili</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kadija</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Corsico</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cerveri</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Chalk</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Trapnell</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Braschi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tinelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Luisetti</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Assessment and management of pulmonary alveolar proteinosis in a reference center.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2013</year>
            <month>Mar</month>
            <day>13</day>
            <volume>8</volume>
            <fpage>40</fpage>
            <pub-id pub-id-type="pmid">23497546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27999.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stanley</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lieschke</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Grail</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Metcalf</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hodgson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gall</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Maher</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Cebon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sinickas</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dunn</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>1994</year>
            <month>Jun</month>
            <day>07</day>
            <volume>91</volume>
            <issue>12</issue>
            <fpage>5592</fpage>
            <page-range>5592-6</page-range>
            <pub-id pub-id-type="pmid">8202532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27999.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barilli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rotoli</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Visigalli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bussolati</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Gazzola</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Kadija</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Rodi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mariani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ruzza</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Luisetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dall'Asta</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>In Lysinuric Protein Intolerance system y+L activity is defective in monocytes and in GM-CSF-differentiated macrophages.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2010</year>
            <month>Nov</month>
            <day>26</day>
            <volume>5</volume>
            <fpage>32</fpage>
            <pub-id pub-id-type="pmid">21110863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27999.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whitsett</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Wert</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Weaver</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>Alveolar surfactant homeostasis and the pathogenesis of pulmonary disease.</article-title>
            <source>Annu Rev Med</source>
            <year>2010</year>
            <volume>61</volume>
            <fpage>105</fpage>
            <page-range>105-19</page-range>
            <pub-id pub-id-type="pmid">19824815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27999.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suzuki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Trapnell</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary Alveolar Proteinosis Syndrome.</article-title>
            <source>Clin Chest Med</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>431</fpage>
            <page-range>431-40</page-range>
            <pub-id pub-id-type="pmid">27514590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27999.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uchida</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nakata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chalk</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sakagami</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Trapnell</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>Standardized serum GM-CSF autoantibody testing for the routine clinical diagnosis of autoimmune pulmonary alveolar proteinosis.</article-title>
            <source>J Immunol Methods</source>
            <year>2014</year>
            <month>Jan</month>
            <day>15</day>
            <volume>402</volume>
            <issue>1-2</issue>
            <fpage>57</fpage>
            <page-range>57-70</page-range>
            <pub-id pub-id-type="pmid">24275678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27999.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nishimura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yamaguchi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Asai</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Katsuda</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ohta</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ohtsuka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kosaka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Matsubara</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yokoe</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kubo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Konno</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Baba</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Clinical significance of serum anti-GM-CSF autoantibody levels in autoimmune pulmonary alveolar proteinosis.</article-title>
            <source>Biomark Med</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>151</fpage>
            <page-range>151-159</page-range>
            <pub-id pub-id-type="pmid">29202602</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27999.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gando</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dur&#x000e9;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Violi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vazquez</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Labarca</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fernandez-Bussy</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Bilateral lung disease, extensive and diffuse. Diagnosis of pulmonary alveolar proteinosis by bronchoscopic cryobiopsy.</article-title>
            <source>Respir Med Case Rep</source>
            <year>2017</year>
            <volume>22</volume>
            <fpage>260</fpage>
            <page-range>260-262</page-range>
            <pub-id pub-id-type="pmid">29021953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27999.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campo</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Luisetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Griese</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trapnell</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Bonella</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Grutters</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nakata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Van Moorsel</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Costabel</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Cottin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ichiwata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Braschi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bonizzoni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Iotti</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Tinelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rodi</surname>
                <given-names>G</given-names>
              </name>
              <collab>WLL International Study Group</collab>
            </person-group>
            <article-title>Whole lung lavage therapy for pulmonary alveolar proteinosis: a global survey of current practices and procedures.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2016</year>
            <month>Aug</month>
            <day>31</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>115</fpage>
            <pub-id pub-id-type="pmid">27577926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27999.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suzuki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Arumugam</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sakagami</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lachmann</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chalk</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sallese</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Trapnell</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Moritz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Malik</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lutzko</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Trapnell</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary macrophage transplantation therapy.</article-title>
            <source>Nature</source>
            <year>2014</year>
            <month>Oct</month>
            <day>23</day>
            <volume>514</volume>
            <issue>7523</issue>
            <fpage>450</fpage>
            <page-range>450-4</page-range>
            <pub-id pub-id-type="pmid">25274301</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27999.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matsuura</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yamaji</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary Alveolar Proteinosis: Crazing-Paving Appearance.</article-title>
            <source>Am J Med</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>131</volume>
            <issue>4</issue>
            <fpage>e153</fpage>
            <page-range>e153-e154</page-range>
            <pub-id pub-id-type="pmid">29191486</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27999.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Punatar</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Kusne</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Blair</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Seville</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Vikram</surname>
                <given-names>HR</given-names>
              </name>
            </person-group>
            <article-title>Opportunistic infections in patients with pulmonary alveolar proteinosis.</article-title>
            <source>J Infect</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>65</volume>
            <issue>2</issue>
            <fpage>173</fpage>
            <page-range>173-9</page-range>
            <pub-id pub-id-type="pmid">22484272</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27999.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seymour</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Presneill</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary alveolar proteinosis: progress in the first 44 years.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2002</year>
            <month>Jul</month>
            <day>15</day>
            <volume>166</volume>
            <issue>2</issue>
            <fpage>215</fpage>
            <page-range>215-35</page-range>
            <pub-id pub-id-type="pmid">12119235</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
